- Direction
- Unknown
- Own history
- —
- Peers
- 100th
- Persistence
- TRANSIENT
· Biological Products, (No Diagnostic Substances)
RESEARCH SNAPSHOT4D Molecular Therapeutics, Inc.'s latest supported as-filed period reports revenue of $3.8M, 25106.7% above the comparable as-filed period. Every value below links to its SEC accession and metric lineage.
No material rule-based research observation currently meets GrossPattern's Insight value threshold. Current state, direction, and filing evidence remain available below.
Separate current dimensions—not a universal score or investment ranking.
A multidimensional view of the latest comparable filing—not a composite score or recommendation.
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
Raw value -1851.34% · OPTIONAL
Yoy · gp.fundamentals.revenue
Raw value 25106.67% · CORE
Level · gp.fundamentals.operating_margin
Raw value -2037.16% · CORE
Level · gp.fundamentals.sbc_revenue_ratio
Raw value 155.62% · OPTIONAL
Business direction, financial quality, capital allocation, and governance evidence remain separate—never collapsed into a recommendation score.
Interpretation boundary Direction describes measurable company fundamentals. Governance reports observable evidence only; it does not grade management character or predict stock returns.
Latest available comparable states within 180 days, normalized with robust median/MAD statistics.
The most important deterministic changes, ranked by magnitude, issuer history, persistence, and accounting profile.
This cluster groups 3 independently calculated changes: Revenue changed across a low base; Operating margin moved 39433617 bp higher; Operating income decreased 29.5%.
3 evidence-backed componentsThis cluster groups 3 independently calculated changes: Revenue changed across a low base; Operating margin moved 39433617 bp higher; Operating income decreased 29.5%.
3 evidence-backed componentsOperating margin changed +39433617 basis points from the comparable as-filed period. The change ranks at the 25th percentile of 4 prior comparable changes.
Each point keeps the date investors could first observe it and its accession.
FDMT · as filed with the SEC · reported-date aware
Direct SEC links, filing dates, report periods, and amendment flags.
0001193125-26-382245SEC ↗4Aug 21, 2026Period Aug 19, 20260001193125-26-361096SEC ↗4Aug 17, 2026Period Aug 13, 20260001193125-26-354313SEC ↗10-QAug 13, 2026Period Jun 30, 20260001193125-26-349173SEC ↗8-KAug 13, 2026Period Aug 13, 20260001193125-26-349160SEC ↗4Aug 5, 2026Period Aug 4, 20260001193125-26-335115SEC ↗4Aug 4, 2026Period Aug 3, 20260001193125-26-333014SEC ↗Transaction semantics distinguish purchases, sales, awards, exercises, withholding, and derivatives.
| Filed / transacted | Reporting owner | Semantics | Shares | Price | Notional | Source |
|---|---|---|---|---|---|---|
| Sep 1, 2026Filed Sep 3, 2026 | Bizily ScottChief Legal Officer | Option ExerciseDirect | 584 | $6 | $3,790 | Form 4 ↗ |
| Sep 1, 2026Filed Sep 3, 2026 | Bizily ScottChief Legal Officer | Open Market SaleDirect | 584 | $14 | $8,176 | Form 4 ↗ |
| Sep 1, 2026Filed Sep 3, 2026 | Bizily ScottChief Legal Officer | Option ExerciseDirect | 584 | $0 | $0 | Form 4 ↗ |
| Aug 19, 2026Filed Aug 21, 2026 | Kirn DavidSee Remarks | Option ExerciseDirect | 50,000 | $4 | $207,000 | Form 4 ↗ |
| Aug 19, 2026Filed Aug 21, 2026 |
GrossPattern stores immutable raw artifacts, accession-scoped facts, parser and metric versions, dependency edges, quality state, and channel-specific publication rights. A restricted or unknown ancestor blocks the page and API automatically.
SEC source policy ↗Operating income changed -29.5% from the comparable as-filed period. The change ranks at the 25th percentile of 4 prior comparable changes.
Revenue changed +25106.7% from the comparable as-filed period. The change ranks at the 75th percentile of 4 prior comparable changes. Relative percentage is de-emphasized because the comparison has a low base.
Net income changed -33.4% from the comparable as-filed period.
SBC / revenue changed -3289771 basis points from the comparable as-filed period. The change ranks at the 0th percentile of 4 prior comparable changes.
Stock-based compensation changed +18.7% from the comparable as-filed period. The change ranks at the 25th percentile of 4 prior comparable changes. This reverses 2 consecutive comparable moves in the opposite direction.
Cash & equivalents changed -8.8% from the comparable as-filed period. The change ranks at the 0th percentile of 4 prior comparable changes.
Method note “Materiality” here is an analytical magnitude band, not a legal conclusion. Full filing-text semantic changes remain unpublished while excerpt rights and review thresholds are unresolved.
Latest supported period in this snapshot: 2026-06-30. Duration facts use direct quarterly or annual SEC contexts; GrossPattern does not manufacture missing Q4 values.
0001193125-26-308409| Option ExerciseDirect |
| 50,000 |
| $0 |
| $0 |
| Form 4 ↗ |
| Aug 19, 2026Filed Aug 21, 2026 | Kirn DavidSee Remarks | Open Market SaleDirect | 43,149 | $15 | $662,622 | Form 4 ↗ |
| Aug 19, 2026Filed Aug 21, 2026 | Kirn DavidSee Remarks | Open Market SaleDirect | 25,927 | $16 | $425,651 | Form 4 ↗ |